Renal involvement in leishmaniasis: A review of the literature

NDT Plus

Volumn 4, Issue 3, 2011, Pages 147-152

  Clementi, Anna ^a,b,c   Battaglia, Giorgio ^d   Floris, Matteo ^a,b,e   Castellino, Pietro ^c   Ronco, Claudio ^a,b   Cruz, Dinna N ^a,b  

^a SAN BORTOLO HOSPITAL   (Italy)

^b International Renal Research Institute Vicenza (IRRIV)   (Italy)

^c Policlinico Universitario   (Italy)

^d Department of Nephrology ^*  (Italy)

^e San Michele Hospital   (Italy)

Author keywords

nephrotoxicity; renal involvement; visceral leishmaniasis

Indexed keywords

ALBUMIN; AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ASPARTATE AMINOTRANSFERASE; CORTICOSTEROID; CREATININE; IMMUNOGLOBULIN G; MEGLUMINE ANTIMONATE; MILTEFOSINE; PAROMOMYCIN; PENTAMIDINE; PROTEIN; RETINOL BINDING PROTEIN; ROTAVIRUS VACCINE; SITAMAQUINE; STIBOGLUCONATE SODIUM;

ABDOMINAL PAIN; ACUTE KIDNEY FAILURE; ANOREXIA; ARTHRALGIA; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BONE MARROW SUPPRESSION; CARDIOTOXICITY; CLINICAL FEATURE; COHORT ANALYSIS; CREATININE BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FEVER; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; GLOMERULONEPHRITIS; GLOMERULUS FILTRATION RATE; HEMATURIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HYPERKALEMIA; HYPOCALCEMIA; HYPOMAGNESEMIA; KIDNEY BIOPSY; KIDNEY DISEASE; KIDNEY TUBULE ACIDOSIS; LEISHMANIA CHAGASI; LEISHMANIASIS; LIVER FUNCTION TEST; MALAISE; MULTICENTER STUDY (TOPIC); MYALGIA; MYCOSIS; NAUSEA; NEPHROGENIC DIABETES INSIPIDUS; NEPHROTOXICITY; NONHUMAN; PANCREATITIS; PHASE 2 CLINICAL TRIAL (TOPIC); PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; PROTEIN URINE LEVEL; PROTEINURIA; PYURIA; REVIEW; RIGOR; SIDE EFFECT; THROMBOPHLEBITIS; VISCERAL LEISHMANIASIS; VOMITING;

EID: 79958175196     PISSN: 17530784     EISSN: 17530792     Source Type: Journal    
DOI: 10.1093/ndtplus/sfr008     Document Type: Review

References (42)

1. Chappuis F, Sundar S, Hailu A et al. Visceral leishmaniasis: what are the needs for diagnosis, treatment and control? Nat Rev Microbiol 2007; 5: 873-882. (Pubitemid 47578388)
2. Sharma U, Singh S. Insect vectors of Leishmania: distribution, physiology and their control. J Vector Borne Dis 2008; 45: 255-272. Review
3. Dutra M, Martinelli R, de Carvalho EM et al. Renal involvement in visceral leishmaniasis. Am J Kidney Dis 1985; 6: 22-27. (Pubitemid 15020967)
4. Salgado Filho N, Ferreira TM, Costa JM. Involvement of the renal function in patients with visceral leishmaniasis (kala-azar). Rev Soc Bras Med Trop 2003; 36: 217-221. (Pubitemid 36753344)
5. Agenor Araújo Lima Verde F, Agenor Araújo Lima Verde F, De Francesco Daher E et al. Renal tubular dysfunction in human visceral leishmaniasis (kala-azar). Clin Nephrol 2009; 71: 492-500.
6. Lima Verde FA, Lima Verde FA, Lima Verde IA et al. Evaluation of renal function in human visceral leishmaniasis (kala-azar): a prospective study on 50 patients from Brazil. J Nephrol 2007; 20: 430-436. (Pubitemid 350081497)
7. Dettwiler S, McKee T, Hadaya K et al. Visceral leishmaniasis in a kidney transplant recipient: parasitic interstitial nephritis, a cause of renal dysfunction. Am J Transplant 2010; 10: 1486-1489.
8. Navarro M, Bonet J, Bonal J et al. Secondary amyloidosis with irreversible acute renal failure caused by visceral leishmaniasis in a patient with AIDS. Nefrologia 2006; 26: 745-746.
9. Alex S, Criado C, Fernández-Guerrero ML et al. Nephrotic syndrome complicating chronic visceral leishmaniasis: re-emergence in patients with AIDS. Clin Nephrol 2008; 70: 65-68. (Pubitemid 352005974)
10. Daher EF, Evangelista LF, Silva Júnior GB et al. Clinical presentation and renal evaluation of human visceral leishmaniasis (kala-azar): a retrospective study of 57 patients in Brazil. Braz J Infect Dis 2008; 12: 329-332.
11. Sartori A, De Oliveira AV, Roque-Barreira MC et al. Immune complex glomerulonephritis in experimental kala-azar. Parasite Immunol 1987; 9: 93-103. (Pubitemid 17026572)
12. de Brito T, Hoshino-Shimizu S, Neto VA et al. Glomerular involvement in human kala-azar. A light, immunofluorescent, and electron microscopic study based on kidney biopsies. Am J Trop Med Hyg 1975; 24: 9-18.
13. Poli A, Abramo F, Mancianti F et al. Renal involvement in canine leishmaniasis. A light-microscopic, immunohistochemical and electron-microscopic study. Nephron 1991; 57: 444-452.
14. Weisinger JR, Pinto A, Velazquez GA et al. Clinical and histological kidney involvement in human kala-azar. Am J Trop Med Hyg 1978; 27(s Pt 1):357-359. (Pubitemid 8312028)
15. Costa FA, Guerra JL, Silva SM et al. CD4(+) T cells participate in the nephropathy of canine visceral leishmaniasis. Braz J Med Biol Res 2000; 33: 1455-1458. (Pubitemid 33621502)
16. Prianti MG, Yokoo M, Saldanha LC et al. Leishmania (Leishmania) chagasi-infected mice as a model for the study of glomerular lesions in visceral leishmaniasis. Braz J Med Biol Res 2007; 40: 819-823.
17. Romero Maroto J, López López C, Mayol MJ et al. Renal and urinary tract leishmaniasis. A disease to keep in mind. Actas Urol Esp 1995; 19: 789-794.
18. Chaigne V, Knefati Y, Lafarge R et al. A patient with visceral leishmaniasis and acute renal failure in necrotizing glomerulonephritis. Nephrologie 2004; 25: 179-183. (Pubitemid 39071134)
19. Veiga JP, Khanam R, Rosa TT et al. Pentavalent antimonial nephrotoxicity in the rat. Rev Inst Med Trop Sao Paulo 1990; 32: 304-309. (Pubitemid 20332670)
20. Rodrigues ML, Costa RS, Souza CS et al. Nephrotoxicity attributed to meglumine antimoniate (Glucantime) in the treatment of generalized cutaneous leishmaniasis. Rev Inst Med Trop Sao Paulo 1999; 41: 33-37. (Pubitemid 29183433)
21. Goldman RD, Koren G. Amphotericin B nephrotoxicity in children. J Pediatr Hematol Oncol 2004; 26: 421-426. (Pubitemid 39025253)
22. Sundar S, Chatterjee M. Visceral leishmaniasis - current therapeutic modalities. Indian J Med Res 2006; 123: 345-352. (Pubitemid 43905574)
23. Olliaro PL, Guerin PJ, Gerstl S et al. Treatment options for visceral leishmaniasis: a systematic review of clinical studies done in India, 1980-2004. Lancet Infect Dis 2005; 5: 763-774.
24. Oliveira MJ, Silva Júnior GB, Abreu KL et al. Risk factors for acute kidney injury in visceral leishmaniasis (Kala-Azar). Am J Trop Med Hyg 2010; 82: 449-453.
25. Lachaal M, Venuto RC. Nephrotoxicity and hyperkalaemia in patients with acquired immunodeficiency syndrome treated with pentamidine. Am J Med 1989; 87: 260-263. (Pubitemid 19234276)
26. Shah GM, Alvarado P, Kirschenbaum MA. Symptomatic hypocalcemia and hypomagnesemia with renal magnesium wasting associated with pentamidine therapy in a patient with AIDS. Am J Med 1990; 89: 380-382. (Pubitemid 20323268)
27. Den Boer M, Davidson RN. Treatment options for visceral leishmaniasis. Expert Rev Anti Infect Ther 2006; 4: 187-197. Review.
28. Sundar S, More DK, Singh MK et al. Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic. Clin Infect Dis 2000; 31: 1104-1107. (Pubitemid 32299375)
29. Varlam DE, Siddiq MM, Parton LA et al. Apoptosis contributes to amphotericin B-induced nephrotoxicity. Antimicrob Agents Chemother 2001; 45: 679-685. (Pubitemid 32182007)
30. Deray G. Amphotericin B nephrotoxicity. J Antimicrob Chemother 2002; 49 (Suppl 1): 37-41. Review.
31. Bern C, Adler-Moore J, Berenguer J et al. Liposomal amphotericin B for the treatment of visceral leishmaniasis. Clin Infect Dis 2006; 43: 917-924. (Pubitemid 44435523)
32. Alvar J, Croft S, Olliaro P. Chemotherapy in the treatment and control of leishmaniasis. Adv Parasitol 2006; 61: 223-274. Review.
33. Sundar S, Mehta H, Suresh AV et al. Amphotericin B treatment for Indian visceral leishmaniasis: conventional versus lipid formulations. Clin Infect Dis 2004; 38: 377-383. (Pubitemid 38200114)
34. Sundar S, Jha TK, Thakur CP et al. Single-dose liposomal amphotericin B in the treatment of visceral leishmaniasis in India: a multicenter study. Clin Infect Dis 2003; 37: 800-804. (Pubitemid 37153659)
35. Sundar S, Jha TK, Thakur CP et al. Low-dose liposomal amphotericin B in refractory Indian visceral leishmaniasis: a multicenter study. Am J Trop Med Hyg 2002; 66: 143-146. (Pubitemid 34755644)
36. Sundar S, Agrawal G, Rai M et al. Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin B: randomised trial. BMJ 2001; 323: 419-422. (Pubitemid 32801392)
37. Aguado JM, Lumbreras C, González-Vidal D et al. Assessment of nephrotoxicity in patients receiving amphotericin B lipid complex: a pharmacosurveillance study in Spain. Clin Microbiol Infect 2004; 10: 785-790. (Pubitemid 39276311)
38. Das VN, Siddiqui NA, Pandey K et al. A controlled, randomized nonblinded clinical trial to assess the efficacy of amphotericin B deoxycholate as compared to pentamidine for the treatment of antimony unresponsive visceral leishmaniasis cases in Bihar, India. Ther Clin Risk Manag 2009; 5: 117-124.
39. Schwarz A, Perez-Canto A. Nephrotoxicity of antiinfective drugs. Int J Clin Pharmacol Ther 1998; 36: 164-167. (Pubitemid 28135038)
40. O'Brien JG, Dong BJ, Coleman RL et al. A 5-year retrospective review of adverse drug reactions and their risk factors in human immunodeficiency virus-infected patients who were receiving intravenous pentamidine therapy for Pneumocystis carinii pneumonia. Clin Infect Dis 1997; 24: 854-859. (Pubitemid 27193867)
41. Sundar S, Jha TK, Thakur CP et al. Injectable paromomycin for visceral leishmaniasis in India. N Engl J Med 2007; 356: 2571-2581. (Pubitemid 46961002)
42. Dietze R, Carvalho SF, Valli LC et al. Phase 2 trial of WR6026, an orally administered 8-aminoquinoline, in the treatment of visceral leishmaniasis caused by Leishmania chagasi. Am J Trop Med Hyg 2001; 65: 685-689. (Pubitemid 34049456)